title: Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults.
abstract: This practice parameter describes treatment with stimulant medication. It uses an evidence-based medicine approach derived from a detailed literature review and expert consultation. Stimulant medications in clinical use include methylphenidate, dextroamphetamine, mixed salts of amphetamine, and pemoline. They carry U.S. Food and Drug Administration indications for the treatment of attention-deficit hyperactivity disorder.
authors.forename: L L
authors.initials: LL
authors.lastname: Greenhill
authors.forename: S
authors.initials: S
authors.lastname: Pliszka
authors.forename: M K
authors.initials: MK
authors.lastname: Dulcan
authors.forename: W
authors.initials: W
authors.lastname: Bernet
authors.forename: V
authors.initials: V
authors.lastname: Arnold
authors.forename: J
authors.initials: J
authors.lastname: Beitchman
authors.forename: R S
authors.initials: RS
authors.lastname: Benson
authors.forename: O
authors.initials: O
authors.lastname: Bukstein
authors.forename: J
authors.initials: J
authors.lastname: Kinlan
authors.forename: J
authors.initials: J
authors.lastname: McClellan
authors.forename: D
authors.initials: D
authors.lastname: Rue
authors.forename: J A
authors.initials: JA
authors.lastname: Shaw
authors.forename: S
authors.initials: S
authors.lastname: Stock
authors.forename: K
authors.initials: K
authors.lastname: Kroeger
mesh_terms: D000293:Adolescent; D000328:Adult; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy*; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use*; D002648:Child; D000075202:Contraindications; D019091:Critical Pathways; D019317:Evidence-Based Medicine; D006801:Humans
chemical_list: D000697:Central Nervous System Stimulants